<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Drug Discov.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Drug Discovery</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Drug Discov.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2674-0338</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1752852</article-id>
<article-id pub-id-type="doi">10.3389/fddsv.2025.1752852</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Specialty Grand Challenge</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Grand challenges in dermatologic drug discovery: four priorities to transform skin disease treatment</article-title>
<alt-title alt-title-type="left-running-head">Grada</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fddsv.2025.1752852">10.3389/fddsv.2025.1752852</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Grada</surname>
<given-names>Ayman</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/818334"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing &#x2013; review and editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Dermatology, School of Medicine, Case Western Reserve University</institution>, <city>Cleveland</city>, <state>OH</state>, <country country="US">United States</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Department of Dermatology, University Hospitals Cleveland Medical Center</institution>, <city>Cleveland</city>, <state>OH</state>, <country country="US">United States</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Ayman Grada, <email xlink:href="mailto:ayman.grada@case.edu">ayman.grada@case.edu</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-05">
<day>05</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>5</volume>
<elocation-id>1752852</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Grada.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Grada</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-05">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<kwd-group>
<kwd>dermatology</kwd>
<kwd>drug discovery</kwd>
<kwd>precision medicine</kwd>
<kwd>cure</kwd>
<kwd>personalized medicine</kwd>
<kwd>challenges</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="91"/>
<page-count count="7"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Dermatologic Drugs</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Dermatology is benefiting from targeted therapies that were unimaginable a decade ago (<xref ref-type="bibr" rid="B29">Fauconnier et al., 2025</xref>). Biologics and JAK inhibitor small molecules now play important roles across multiple conditions, especially in psoriasis and atopic dermatitis, while emerging platforms such as multi-specific antibodies are under active evaluation (<xref ref-type="bibr" rid="B11">Bieber, 2022</xref>; <xref ref-type="bibr" rid="B5">Armstrong et al., 2025</xref>; <xref ref-type="bibr" rid="B88">Zhang T. et al., 2025</xref>; <xref ref-type="bibr" rid="B21">Davis et al., 2024</xref>). Small-molecule inhibition of the Janus kinase&#x2013;signal transducer and activator of transcription (JAK&#x2013;STAT) pathway has broadened available options in conditions including atopic dermatitis, alopecia areata, and vitiligo, and has influenced how efficacy endpoints and treatment targets are defined in clinical studies and practice (<xref ref-type="bibr" rid="B51">Lv et al., 2024</xref>; <xref ref-type="bibr" rid="B33">Fujita et al., 2025</xref>; <xref ref-type="bibr" rid="B30">Ferreira et al., 2025</xref>; <xref ref-type="bibr" rid="B70">Silverberg et al., 2024a</xref>).</p>
<p>These advances are cause for optimism, but they have not eliminated the central problem that still defines most of our practice: even our best therapeutics often fail to provide lasting, universal, or curative responses (<xref ref-type="bibr" rid="B36">Gelfand, 2024</xref>). Many patients never respond. Others lose response with time. For a large share of conditions, including acne (affecting 85% of adolescents), fibrosing disorders such as scleroderma, chronic pigmentary conditions such as melasma, and numerous genodermatoses such as epidermolysis bullosa, our tools remain limited. For other critical areas including non-melanoma skin cancers (among the most commonly diagnosed cancers worldwide and the most common cancer in the United States) (<xref ref-type="bibr" rid="B73">Society, 2019</xref>), actinic keratoses, the most common diagnosis at U.S. dermatology office visits (<xref ref-type="bibr" rid="B42">Grada et al., 2022</xref>) with pooled global prevalence of about 14% (<xref ref-type="bibr" rid="B37">George et al., 2024</xref>), and chronic cutaneous wounds affecting an estimated 0.2%&#x2013;1% of the population worldwide (<xref ref-type="bibr" rid="B28">Falanga et al., 2022</xref>; <xref ref-type="bibr" rid="B54">Martinengo et al., 2019</xref>), a burden expected to rise with population aging (<xref ref-type="bibr" rid="B59">Pang et al., 2025</xref>), current therapies often provide incomplete responses or require repeated invasive procedures. Even for diseases where drugs are highly effective, treatment is usually indefinite and relapse after treatment withdrawal is common across inflammatory dermatoses, and many patients require ongoing therapy to maintain disease control (<xref ref-type="bibr" rid="B55">Masson et al., 2022</xref>; <xref ref-type="bibr" rid="B19">Chen M. et al., 2025</xref>).</p>
<p>The Dermatologic Drugs section of Frontiers in Drug Discovery exists to close this gap by connecting mechanistic discovery to clinically meaningful dermatologic therapies.</p>
</sec>
<sec id="s2">
<title>Grand challenge 1: the precision challenge</title>
<p>Precision in dermatology begins with acknowledging that diseases such as atopic dermatitis and psoriasis are syndromes rather than single entities. They consist of overlapping phenotypes that share clinical signs but diverge in molecular drivers, comorbidities, trajectories, and responses to therapy (<xref ref-type="bibr" rid="B60">Park et al., 2024</xref>; <xref ref-type="bibr" rid="B34">Fyhrquist et al., 2025</xref>; <xref ref-type="bibr" rid="B18">Chandran et al., 2024</xref>; <xref ref-type="bibr" rid="B39">Glickman et al., 2025</xref>). For instance, while currently approved biologic therapies have revolutionized atopic dermatitis treatment, around 40% or more of patients in clinical trials do not reach commonly used response thresholds such as EASI-75 at 16&#xa0;weeks (<xref ref-type="bibr" rid="B72">Simpson et al., 2016</xref>; <xref ref-type="bibr" rid="B85">Wollenberg et al., 2021</xref>; <xref ref-type="bibr" rid="B69">Silverberg et al., 2023</xref>; <xref ref-type="bibr" rid="B71">Silverberg et al., 2024b</xref>). Identifying these non-responders before treatment initiation would spare months of ineffective therapy and progression. The current standard of care remains a sequential trial of mechanisms, with each attempt consuming time and exposing patients to fluctuating symptoms and potential risks. The central task is to shift from trial and error to patient-level prediction at baseline, and to maintain that precision longitudinally as the disease and the patient evolve.</p>
<p>The field has made progress with diagnostic and prognostic biomarkers, but the most impactful tools are likely to be predictive biomarkers that match an individual patient to a specific disease mechanism and dosing strategy before treatment begins. Real advances will depend on integrating multi-omic measurements (genomics, transcriptomics, proteomics, metabolomics and related layers) with high fidelity clinical phenotyping, imaging, digital biomarkers from wearables, patient reported outcomes, and longitudinal data from routine care. In acne, for example, successive genome wide association studies and meta-analyses now implicate about 50 genetic risk loci, enriching for genes that regulate hair follicle development, pilosebaceous unit structure, lipid metabolism, and stem cell lineage decisions, and pointing toward therapeutic targets that extend beyond traditional anti-inflammatory approaches (<xref ref-type="bibr" rid="B76">Teder-Laving et al., 2024</xref>).</p>
<p>Emerging computational approaches such as digital twins, virtual patient models that integrate multiscale biological and clinical data to simulate individual treatment responses, could enable truly personalized therapeutic selection and dosing optimization (<xref ref-type="bibr" rid="B62">Primiero et al., 2025</xref>; <xref ref-type="bibr" rid="B3">Akbarialiabad et al., 2025a</xref>). Predictive signatures will need to be transportable across clinical sites, ancestries, and health systems, and evaluated not only for statistical discrimination, but also for practical decision value such as shorter time to disease control, fewer ineffective treatment cycles, and improved quality of life. Studies that embed pharmacogenomic and pharmacotranscriptomic testing into routine clinical workflows can demonstrate how precision prescribing performs in real-world clinics rather than only in tightly controlled trials. Adaptive, biomarker-anchored trial designs, including enrichment strategies and N-of-1 frameworks, can reduce uncertainty while minimizing prolonged exposure to ineffective options (<xref ref-type="bibr" rid="B10">Bhatt and Mehta, 2016</xref>; <xref ref-type="bibr" rid="B6">Augustine et al., 2024</xref>). Finally, authoritative reviews that synthesize the fragmented biomarker landscape and propose standard panels, fit-for-purpose thresholds, and minimal reporting standards will be essential to accelerate adoption.</p>
<p>We should measure the success of this challenge by prospective validation that includes external cohorts, by prespecified thresholds that clinicians can use at the bedside, and by transparent decision analyses that show how predictions change clinical outcomes. When a model helps a clinician select the first therapy that works and informs when to continue, taper, or switch, the promise of precision becomes real.</p>
</sec>
<sec id="s3">
<title>Grand challenge 2: the translational challenge</title>
<p>The second challenge concerns the reliability of the bridge from discovery to proof of concept in patients. Many agents that look compelling in preclinical studies do not survive early clinical testing (<xref ref-type="bibr" rid="B75">Swindell et al., 2017</xref>). For example, ROR&#x3b3;t, the lineage-defining transcription factor for Th17 cells, emerged as a highly attractive psoriasis target based on strong genetic and mechanistic data and robust efficacy of IL-17/IL-23 blockade in murine and <italic>ex vivo</italic> models. Yet systemic ROR&#x3b3;t inhibition with the oral small molecule BI 730357 produced only moderate PASI responses in a phase II trial of moderate-to-severe plaque psoriasis, with PASI-75 rates around 30% at the highest dose&#x2013;clearly below the efficacy typically seen with IL-17 or IL-23 biologics&#x2013;and its long-term extension was ultimately discontinued because of limited efficacy and non-human carcinogenicity findings (<xref ref-type="bibr" rid="B40">Gooderham et al., 2025</xref>; <xref ref-type="bibr" rid="B2">Akbarialiabad and Bunick, 2025</xref>). These outcomes underscore the limited predictive value of many commonly used models: acute cytokine-driven mouse models and simple two-dimensional cultures capture only fragments of human disease and often fail to reproduce its chronicity, spatial architecture, and multicellular crosstalk (<xref ref-type="bibr" rid="B35">Gangwar et al., 2022</xref>). Meanwhile, artificial-intelligence and machine-learning approaches have raised expectations for faster target discovery and design, but their output remains hypothetical until it is rigorously validated in experimental systems and early-phase trials that faithfully recapitulate the relevant human biology (<xref ref-type="bibr" rid="B8">Bender and Cort&#xe9;s-Ciriano, 2021</xref>; <xref ref-type="bibr" rid="B44">Hasselgren and Oprea, 2024</xref>; <xref ref-type="bibr" rid="B89">Zhang K. et al., 2025</xref>).</p>
<p>The immediate need is a clear framework that prioritizes human-relevant models and sets standards for evaluating AI-assisted discovery. Advanced three-dimensional skin organoids, microengineered skin-on-a-chip systems, and humanized mouse models can capture more of the real tissue architecture and multicellular signaling than conventional two-dimensional cultures or short-term inflammatory mouse models (<xref ref-type="bibr" rid="B77">Teertam et al., 2025</xref>; <xref ref-type="bibr" rid="B64">Qu&#xed;lez et al., 2024</xref>). <italic>Ex vivo</italic> human skin and other tissue explants can then act as a practical bridge between <italic>in silico</italic> predictions and <italic>in vivo</italic> responses (<xref ref-type="bibr" rid="B81">Wang et al., 2023</xref>; <xref ref-type="bibr" rid="B56">Neil et al., 2020</xref>). They allow controlled testing of target engagement, downstream pathway modulation, and pharmacodynamic effects in an intact human microenvironment (<xref ref-type="bibr" rid="B61">P&#xe9;rez-Salas et al., 2023</xref>). Model-informed translational pharmacology that links pharmacokinetics, pharmacodynamics, spatial tissue profiling, and imaging can support rational dose selection and increase the chances that early-phase trials test an exposure that truly matches the intended mechanism of action (<xref ref-type="bibr" rid="B25">Dudal et al., 2022</xref>; <xref ref-type="bibr" rid="B58">Nordmann et al., 2024</xref>).</p>
<p>Equally important is a culture of prospective and transparent validation for computational methods. Studies that pit AI-nominated targets and designs against traditional pipelines, that include negative controls, blinding, and preregistered analysis plans, and that report failure modes will separate durable advances from fragile demonstrations. Regulatory science contributions that define fit-for-purpose validation standards, share reference materials, and harmonize assays will make it easier for the community to compare results and build upon them.</p>
<p>We will know this challenge is being met when model performance correlates with Phase 2 outcomes across diverse programs, when mechanistic evidence convincingly links target engagement to clinically meaningful biomarkers, and when early clinical studies fail less often because the preclinical package was genuinely predictive.</p>
</sec>
<sec id="s4">
<title>Grand challenge 3: the modality challenge</title>
<p>The third challenge is to broaden what we consider &#x201c;druggable&#x201d; and how therapies actually reach their cutaneous targets. Small molecules and monoclonal antibodies will remain essential, but on their own they cannot cover the full range of relevant biology. Many key drivers of disease lie in transcriptional programs, intracellular protein&#x2013;protein interactions, and genetic variants that are hard to reach with conventional modalities. Addressing these targets will require adapting nucleic acid therapeutics, gene-editing systems, protein degraders and molecular glues, bispecific antibodies, cell-mediated delivery systems (including engineered immune and stem cells), and other advanced platforms to the specific barriers and opportunities of human skin (<xref ref-type="bibr" rid="B17">Chai et al., 2025</xref>; <xref ref-type="bibr" rid="B47">Hwang et al., 2025</xref>; <xref ref-type="bibr" rid="B91">Zhong et al., 2024</xref>; <xref ref-type="bibr" rid="B9">Bhat and Garibyan, 2022</xref>; <xref ref-type="bibr" rid="B68">Shqair et al., 2025</xref>).</p>
<p>Skin is both an obstacle and an ally. Its barrier function protects the host but also makes delivery difficult; at the same time, it allows local administration and direct visualization of response (<xref ref-type="bibr" rid="B15">Brito et al., 2024</xref>; <xref ref-type="bibr" rid="B50">Lee et al., 2024</xref>; <xref ref-type="bibr" rid="B90">Zhao et al., 2024</xref>). Early examples such as topical ruxolitinib cream for vitiligo and atopic dermatitis illustrate how formulation and delivery innovation can turn a systemic mechanism into a targeted cutaneous therapy.</p>
<p>Further progress will depend on understanding the structure&#x2013;function relationships that govern penetration, cellular targeting, intracellular trafficking, and expression within keratinocytes, fibroblasts, melanocytes, endothelial and immune cells, and adnexal structures. Dissolving microneedles, optimized lipid nanoparticles, polymeric or extracellular vesicle&#x2013;based carriers, follicular targeting systems, and intradermal or regional delivery approaches offer ways to concentrate drugs in specific skin compartments while limiting systemic exposure (<xref ref-type="bibr" rid="B86">Wu C. et al., 2024</xref>; <xref ref-type="bibr" rid="B43">Guri-Lamce et al., 2024</xref>; <xref ref-type="bibr" rid="B66">Raina et al., 2023</xref>; <xref ref-type="bibr" rid="B48">Jung et al., 2006</xref>). The same delivery strategies can also be used to repurpose known agents by reshaping local exposure and improving benefit&#x2013;risk profiles without altering the pharmacology of the active molecule.</p>
<p>Studies that quantify delivery to defined skin compartments, show on-target activity in the intended cell types, and clearly describe local tolerability will be the most informative for moving new platforms forward (<xref ref-type="bibr" rid="B79">Tsakalozou et al., 2023</xref>; <xref ref-type="bibr" rid="B24">Djuris et al., 2024</xref>; <xref ref-type="bibr" rid="B45">Hsiao et al., 2024</xref>). In parallel, Chemistry, Manufacturing, and Controls (CMC) and manufacturability descriptions for cutaneous advanced therapies&#x2013;including stability data, scalable processes, and well-defined critical quality attributes&#x2013;can accelerate translation by resolving practical barriers that often stall promising concepts. Reviews that organize structure&#x2013;function principles for skin-directed delivery into clear design rules would serve as key reference points for both academic groups and industry teams.</p>
<p>The field will know it is making real progress when platforms reliably achieve therapeutic concentrations in targeted cutaneous cells, when pharmacodynamic evidence shows specific pathway modulation with acceptable local and systemic safety, and when integrated translational packages (pharmacology, toxicology, and CMC) are routinely mature enough to support first-in-human studies for modalities that have not traditionally been used in dermatology (<xref ref-type="bibr" rid="B80">Walford et al., 2023</xref>; <xref ref-type="bibr" rid="B31">Food and Administration, 2008</xref>).</p>
</sec>
<sec id="s5">
<title>Grand challenge 4: the curative challenge</title>
<p>The fourth challenge is the most ambitious. Many inflammatory and pigmentary diseases relapse after treatment withdrawal because tissues retain a &#x201c;memory&#x201d; of disease (<xref ref-type="bibr" rid="B32">Francis et al., 2024</xref>; <xref ref-type="bibr" rid="B78">Tian and Lai, 2022</xref>). This memory likely includes pathogenic tissue-resident T-cell populations that persist in previously affected sites, alongside durable changes in keratinocytes, fibroblasts, endothelial cells, and other structural cells that keep the tissue in a primed state. Neuroimmune circuits, vascular and stromal remodeling, and epigenetic marks may all reinforce this susceptibility. Current drugs generally suppress inflammatory cascades without fully erasing these tissue programs (<xref ref-type="bibr" rid="B36">Gelfand, 2024</xref>; <xref ref-type="bibr" rid="B12">Bieber, 2023</xref>; <xref ref-type="bibr" rid="B13">Bieber, 2025</xref>). In this Perspective, we define sustained drug-free remission as maintenance of clinically meaningful disease control for at least 12&#xa0;months after complete withdrawal of active therapy. Achieving this consistently will require strategies that disrupt the maintenance and reactivation of disease memory and that actively restore healthy tissue states rather than simply quieting inflammation (<xref ref-type="bibr" rid="B14">Blauvelt, 2022</xref>).</p>
<p>Beyond chronic inflammatory dermatoses, the curative challenge extends to skin cancers, precancerous lesions, and chronic wounds. In actinic keratoses and field cancerization, most lesions never progress, yet the surrounding photodamaged field harbors clonally altered keratinocytes and represents a reservoir of subclinical disease (<xref ref-type="bibr" rid="B1">Aggarwal et al., 2024</xref>; <xref ref-type="bibr" rid="B38">Gilchrest, 2021</xref>). Therapies that clear both visible and subclinical lesions while normalizing keratinocyte differentiation programs could reduce progression to cutaneous squamous cell carcinoma and decrease the need for repeated destructive procedures (<xref ref-type="bibr" rid="B83">Weinstock, 2008</xref>; <xref ref-type="bibr" rid="B84">Weinstock et al., 2018</xref>). For high-risk or advanced squamous cell carcinoma, immune checkpoint inhibitors have already transformed outcomes (<xref ref-type="bibr" rid="B74">Stonesifer et al., 2021</xref>), while in the field-cancerization setting, field-directed regimens&#x2013;including topical immunotherapies, photodynamic therapy, and combination strategies&#x2013;aim for comprehensive field clearance rather than lesion-by-lesion ablation.</p>
<p>In chronic wounds, failed regeneration, persistent inflammation, and cellular senescence trap tissues in a non-healing state (<xref ref-type="bibr" rid="B26">Falanga, 2005</xref>). Strategies that reactivate dormant regenerative programs, modulate senescent and dysfunctional cell populations, and restore appropriate growth factor and matrix signaling could transform outcomes for patients with diabetic foot ulcers, venous leg ulcers, pressure injuries, and other non-healing wounds. Emerging regenerative approaches&#x2013;including bioengineered skin substitutes, stem-cell-based therapies, extracellular-vesicle and scaffold platforms, and pro-resolving mediators&#x2013;provide concrete routes to rebuild architecture and re-establish tissue homeostasis (<xref ref-type="bibr" rid="B41">Grada and Falanga, 2016</xref>; <xref ref-type="bibr" rid="B27">Falanga et al., 2021</xref>; <xref ref-type="bibr" rid="B82">Wei et al., 2022</xref>).</p>
<p>Progress on this challenge will depend on better human mapping of disease trajectories. Longitudinal and spatial analyses that track how resident immune cells and stromal compartments are established, maintained, and reactivated in human skin can identify which cell states must be depleted, displaced, or reprogrammed (<xref ref-type="bibr" rid="B87">Wu D. et al., 2024</xref>). Mechanistic studies should test whether targeting pathogenic tissue-resident populations, or their sustaining cytokine networks, can reset the local milieu safely. Interventions might combine short, intensive therapy to extinguish active pathways with biomarker-guided tapering and structured withdrawal (<xref ref-type="bibr" rid="B22">Deng et al., 2024</xref>). Trials should prespecify remission definitions, relapse biomarkers, and stopping rules that are clinically meaningful and reproducible.</p>
<p>In fibrosing conditions and scarring genodermatoses, regenerative strategies that rebuild architecture and barrier function will need to work alongside immunomodulation. Evidence that this challenge is being met will include biomarkers that prospectively identify readiness for withdrawal, sustained control after planned discontinuation, and molecular signatures showing a shift toward healthy tissue states. For cancer prevention, success means durable field clearance with reduced progression to invasive disease. For wound healing, it means complete and stable closure with restoration of functional skin. Authoritative reviews that integrate emerging frameworks for disease modification, cancer prevention, and tissue regeneration in skin will help knit together insights from inflammation biology, oncology, and regenerative medicine.</p>
</sec>
<sec id="s6">
<title>Cross-cutting enablers</title>
<p>Each of the four challenges depends on shared technical and societal foundations. At the core are standardized outcomes and biomarker platforms: harmonized clinical measures, imaging, digital readouts, and patient-reported outcomes, together with validated pharmacodynamic and predictive biomarkers, are essential for comparing interventions across studies and for meta-analyses that can inform practice and policy (<xref ref-type="bibr" rid="B49">Kottner et al., 2018</xref>; <xref ref-type="bibr" rid="B63">Prinsen et al., 2019</xref>). Patient engagement and co-design align research priorities with lived experience and ensure outcomes measure what matters to patients (<xref ref-type="bibr" rid="B63">Prinsen et al., 2019</xref>). Data and model sharing, clear reporting, and where feasible open code reduce duplication and improve reproducibility, while AI/ML and emerging digital-twin approaches require well-annotated, diverse datasets to be trustworthy.</p>
<p>Diversity and equity must be built in from the outset, with enrollment and validation across skin tones, ancestries, and geographies so that discoveries are generalizable. Global health perspectives are critical because skin disease burden is high in resource-limited settings where access to advanced diagnostics and therapeutics is limited. Climate change is emerging as a modifier of skin disease patterns: rising temperatures, air pollution, ultraviolet exposure, and extreme weather events are all associated with shifts in the prevalence, severity, and triggers of many dermatoses (<xref ref-type="bibr" rid="B7">Belzer and Parker, 2023</xref>; <xref ref-type="bibr" rid="B23">Dhillon and Parker, 2025</xref>). Even more extreme environments, such as spaceflight, reveal how skin adapts under combined radiation, microgravity, and confined-habitat stressors (<xref ref-type="bibr" rid="B4">Akbarialiabad et al., 2025b</xref>; <xref ref-type="bibr" rid="B65">Radstake et al., 2022</xref>). Astronauts frequently develop erythema, xerosis, pruritus, delayed wound healing, and features of accelerated skin aging, providing unique models for barrier disruption, impaired repair, and microbiome change that can inform terrestrial therapies (<xref ref-type="bibr" rid="B4">Akbarialiabad et al., 2025b</xref>; <xref ref-type="bibr" rid="B57">Niknam et al., 2025</xref>; <xref ref-type="bibr" rid="B16">Caswell and Eshelby, 2022</xref>).</p>
<p>Public&#x2013;private partnerships can accelerate translation by pairing academic innovation with industrial scale and development capabilities. Real-world learning systems, including prospective registries, pragmatic and decentralized trials, and systematic durability and safety surveillance, can embed biomarker sampling, switching rules, and structured withdrawal into routine care (<xref ref-type="bibr" rid="B20">Chen J. et al., 2025</xref>; <xref ref-type="bibr" rid="B67">Rogers et al., 2022</xref>). Regulatory and policy science can provide fit-for-purpose pathways for biomarker and model qualification and for novel modalities and combinations. An emerging frontier that intersects all four challenges is the cutaneous microbiome. Dysbiosis contributes to multiple inflammatory, infectious, and neoplastic skin conditions, and microbiome-targeted interventions&#x2013;including prebiotics, probiotics, postbiotics, bacteriophages, and engineered commensals&#x2013;are beginning to show clinical promise as adjuncts or alternatives to traditional therapies (<xref ref-type="bibr" rid="B46">H&#xfc;lp&#xfc;sch et al., 2024</xref>; <xref ref-type="bibr" rid="B52">MacGibeny et al., 2024a</xref>; <xref ref-type="bibr" rid="B53">MacGibeny et al., 2024b</xref>).</p>
</sec>
<sec id="s7">
<title>What we seek in frontiers in drug discovery: dermatologic drugs</title>
<p>The Dermatologic Drugs section invites:<list list-type="bullet">
<list-item>
<p>Original Research: Mechanistic studies, target validation, delivery innovation</p>
</list-item>
<list-item>
<p>Clinical Trials: Phase 1&#x2013;4 studies with biomarker integration</p>
</list-item>
<list-item>
<p>Brief Research Reports: Negative results, reproducibility studies</p>
</list-item>
<list-item>
<p>Reviews: Systematic reviews, meta-analyses, state-of-the-art reviews</p>
</list-item>
<list-item>
<p>Perspectives: Regulatory science, health economics, patient perspectives</p>
</list-item>
</list>
</p>
<p>We particularly encourage authoritative reviews that define unmet needs with specificity, propose coherent research agendas, and establish shared terminology. Manuscripts should emphasize prespecified analysis plans where appropriate, external validation when feasible, and clear articulation of clinical relevance. Studies that release data and methods in line with community standards will accelerate progress by enabling independent verification and reuse. These priorities, along with example study types and markers of progress for each grand challenge, are summarized in <xref ref-type="sec" rid="s14">Supplementary Table S1</xref>.</p>
</sec>
<sec sec-type="conclusion" id="s8">
<title>Conclusion</title>
<p>Precision, Translational, Modality, and Curative challenges are interdependent. Better models will increase the yield of AI-assisted discovery. New delivery systems will expand the range of targets we can engage safely in human skin. Predictive biomarkers will allow focused, efficient trials that test whether we are modifying disease rather than only suppressing it. Together, these efforts can move dermatology from symptomatic control to treatment-free disease control and potential cure.</p>
<p>The tools to meet these challenges already exist. We invite colleagues across academia, industry, and policy to bring forward work that is ambitious, testable, and centered on patient benefit. The Dermatologic Drugs section stands ready to disseminate studies that advance SDG 3 and to help shape a future in which long-term disease quiescence is a standard expectation and cure is a realistic objective. We invite submissions that challenge conventional approaches, embrace innovative methodologies, and prioritize patient-centered outcomes. Together, these efforts can move dermatology from symptomatic control to treatment-free disease control and, ultimately, to curative strategies for selected conditions.</p>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="s9">
<title>Author contributions</title>
<p>AG: Writing &#x2013; review and editing, Formal Analysis, Supervision, Project administration, Writing &#x2013; original draft, Methodology, Resources, Conceptualization, Investigation.</p>
</sec>
<sec sec-type="COI-statement" id="s11">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s12">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s13">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s14">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fddsv.2025.1752852/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fddsv.2025.1752852/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Edited and Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1261742/overview">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aggarwal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Puyana</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chandan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jetter</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tsoukas</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Field cancerization therapies for the management of actinic keratosis: an updated review</article-title>. <source>Am. J. Clin. Dermatol.</source> <volume>25</volume> (<issue>3</issue>), <fpage>391</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1007/s40257-023-00839-8</pub-id>
<pub-id pub-id-type="pmid">38351246</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarialiabad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bunick</surname>
<given-names>C. G.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Revisiting ROR&#x3b3;t inhibition in plaque psoriasis: lessons learned from BI 730357</article-title>. <source>J. Investigative Dermatol.</source> <volume>145</volume> (<issue>8</issue>), <fpage>1831</fpage>&#x2013;<lpage>1834</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2025.03.036</pub-id>
<pub-id pub-id-type="pmid">40423599</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarialiabad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pasdar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Murrell</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Mostafavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shakil</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Safaee</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2025a</year>). <article-title>Enhancing randomized clinical trials with digital twins</article-title>. <source>npj Syst. Biol. Appl.</source> <volume>11</volume> (<issue>1</issue>), <fpage>110</fpage>. <pub-id pub-id-type="doi">10.1038/s41540-025-00592-0</pub-id>
<pub-id pub-id-type="pmid">41044102</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarialiabad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Parvar</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Grada</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2025b</year>). <article-title>Space-related dermatoses (SRD)</article-title>. <source>Clin. Dermatol</source>. <pub-id pub-id-type="doi">10.1016/j.clindermatol.2025.10.006</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Blauvelt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Callis Duffin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Psoriasis</article-title>. <source>Nat. Rev. Dis. Prim.</source> <volume>11</volume> (<issue>1</issue>), <fpage>45</fpage>. <pub-id pub-id-type="doi">10.1038/s41572-025-00630-5</pub-id>
<pub-id pub-id-type="pmid">40571687</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Augustine</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Timothy</surname>
<given-names>W. Y.</given-names>
</name>
<name>
<surname>Finkel</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>N-of-1 studies in an era of precision medicine</article-title>. <source>JAMA</source> <volume>332</volume> (<issue>16</issue>), <fpage>1386</fpage>&#x2013;<lpage>1387</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2024.14637</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belzer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>E. R.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Climate change, skin health, and dermatologic disease: a guide for the dermatologist</article-title>. <source>Am. J. Clin. Dermatol.</source> <volume>24</volume> (<issue>4</issue>), <fpage>577</fpage>&#x2013;<lpage>593</lpage>. <pub-id pub-id-type="doi">10.1007/s40257-023-00770-y</pub-id>
<pub-id pub-id-type="pmid">37336870</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bender</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cort&#xe9;s-Ciriano</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet</article-title>. <source>Drug Discovery Today</source> <volume>26</volume> (<issue>2</issue>), <fpage>511</fpage>&#x2013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.12.009</pub-id>
<pub-id pub-id-type="pmid">33346134</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhat</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Garibyan</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The potential of CRISPR-guided therapies in the dermatology clinic</article-title>. <source>JID Innov.</source> <volume>2</volume> (<issue>2</issue>), <fpage>100103</fpage>. <pub-id pub-id-type="doi">10.1016/j.xjidi.2022.100103</pub-id>
<pub-id pub-id-type="pmid">35265937</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatt</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Adaptive designs for clinical trials</article-title>. <source>N. Engl. J. Med.</source> <volume>375</volume> (<issue>1</issue>), <fpage>65</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1510061</pub-id>
<pub-id pub-id-type="pmid">27406349</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bieber</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Atopic dermatitis: an expanding therapeutic pipeline for a complex disease</article-title>. <source>Nat. Rev. Drug Discovery</source> <volume>21</volume> (<issue>1</issue>), <fpage>21</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-021-00266-6</pub-id>
<pub-id pub-id-type="pmid">34417579</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bieber</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Disease modification in inflammatory skin disorders: opportunities and challenges</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>22</volume> (<issue>8</issue>), <fpage>662</fpage>&#x2013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-023-00735-0</pub-id>
<pub-id pub-id-type="pmid">37443275</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bieber</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification</article-title>. <source>Ann. Allergy Asthma Immunol.</source> <volume>134</volume> (<issue>2</issue>), <fpage>144</fpage>&#x2013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.anai.2024.09.022</pub-id>
<pub-id pub-id-type="pmid">39383939</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Blauvelt</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <source>Resident memory T cells in psoriasis: key to a cure?</source>. <publisher-loc>Los Angeles, CA</publisher-loc>: <publisher-name>SAGE Publications Sage CA</publisher-name>, <fpage>157</fpage>&#x2013;<lpage>159</lpage>.</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bin</surname>
<given-names>B.-H.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Skin structure, physiology, and pathology in topical and transdermal drug delivery</article-title>. <source>Pharmaceutics</source> <volume>16</volume> (<issue>11</issue>), <fpage>1403</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics16111403</pub-id>
<pub-id pub-id-type="pmid">39598527</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caswell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Eshelby</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Skin microbiome considerations for long haul space flights</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>10</volume>, <fpage>956432</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2022.956432</pub-id>
<pub-id pub-id-type="pmid">36158225</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Siegwart</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R. C.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Nucleic acid therapy for the skin</article-title>. <source>J. Investigative Dermatol.</source> <volume>145</volume> (<issue>4</issue>), <fpage>780</fpage>&#x2013;<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2024.07.029</pub-id>
<pub-id pub-id-type="pmid">39269387</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>de Vlam</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Biomarkers in psoriasis and psoriatic arthritis: where are we now?</article-title>. <source>J. Rheumatol.</source> <volume>51</volume> (<issue>Suppl. 2</issue>), <fpage>74</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.3899/jrheum.2024-0260</pub-id>
<pub-id pub-id-type="pmid">39009392</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2025a</year>). <article-title>Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis</article-title>. <source>Front. Med.</source> <volume>12</volume>, <fpage>1585368</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2025.1585368</pub-id>
<pub-id pub-id-type="pmid">40880757</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Daizadeh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y. L.</given-names>
</name>
<etal/>
</person-group> (<year>2025b</year>). <article-title>Decentralized clinical trials in the era of real&#x2010;world evidence: a statistical perspective</article-title>. <source>Clin. Translational Sci.</source> <volume>18</volume> (<issue>2</issue>), <fpage>e70117</fpage>. <pub-id pub-id-type="doi">10.1111/cts.70117</pub-id>
<pub-id pub-id-type="pmid">39972404</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Drucker</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Alikhan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bercovitch</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Darr</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies</article-title>. <source>J. Am. Acad. Dermatol.</source> <volume>90</volume> (<issue>2</issue>), <fpage>e43</fpage>&#x2013;<lpage>e56</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2023.08.102</pub-id>
<pub-id pub-id-type="pmid">37943240</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The role and therapeutic strategies for tissue&#x2010;resident memory T cells, central memory T cells, and effector memory T cells in psoriasis</article-title>. <source>Immunology</source> <volume>173</volume> (<issue>3</issue>), <fpage>470</fpage>&#x2013;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1111/imm.13843</pub-id>
<pub-id pub-id-type="pmid">39136109</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhillon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>E. R.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Climate change, harmful algal blooms, and cutaneous disease</article-title>. <source>JAAD Rev.</source> <volume>4</volume>, <fpage>156</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdrv.2025.02.012</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djuris</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cvijic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Djekic</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Model-informed drug development: <italic>in silico</italic> assessment of drug bioperformance following oral and percutaneous administration</article-title>. <source>Pharmaceuticals</source> <volume>17</volume> (<issue>2</issue>), <fpage>177</fpage>. <pub-id pub-id-type="doi">10.3390/ph17020177</pub-id>
<pub-id pub-id-type="pmid">38399392</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bissantz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>David-Pierson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Driessen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Koller</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Translating pharmacology models effectively to predict therapeutic benefit</article-title>. <source>Drug Discov. Today</source> <volume>27</volume> (<issue>6</issue>), <fpage>1604</fpage>&#x2013;<lpage>1621</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2022.03.009</pub-id>
<pub-id pub-id-type="pmid">35304340</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falanga</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Wound healing and its impairment in the diabetic foot</article-title>. <source>Lancet</source> <volume>366</volume> (<issue>9498</issue>), <fpage>1736</fpage>&#x2013;<lpage>1743</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67700-8</pub-id>
<pub-id pub-id-type="pmid">16291068</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falanga</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Otero</surname>
<given-names>V. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Autologous cultured bone marrow-derived mesenchymal stem cells in a fibrin spray to treat venous ulcers: a randomized controlled double-blind pilot study</article-title>.</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falanga</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Isseroff</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Soulika</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Romanelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kapp</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Chronic wounds</article-title>. <source>Nat. Rev. Dis. Prim.</source> <volume>8</volume> (<issue>1</issue>), <fpage>50</fpage>. <pub-id pub-id-type="doi">10.1038/s41572-022-00377-3</pub-id>
<pub-id pub-id-type="pmid">35864102</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fauconnier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Melis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berenbeck</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pio</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Croisier</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Trends in the drug target landscape for autoimmune diseases</article-title>. <source>Nat. Rev. Drug Discovery</source> <volume>24</volume>, <fpage>415</fpage>&#x2013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-025-00061-7</pub-id>
<pub-id pub-id-type="pmid">40181113</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>JAK inhibitors for the treatment of vitiligo: current evidence and emerging therapeutic potential</article-title>. <source>Drugs</source> <volume>85</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-025-02246-1</pub-id>
<pub-id pub-id-type="pmid">40996476</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Food</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Administration</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2008</year>). <source>Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs)</source>. <publisher-name>Center for Biologics Evaluation and Research</publisher-name>.</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Capon</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Haniffa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mahil</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Inflammatory memory in psoriasis: from remission to recurrence</article-title>. <source>J. Allergy Clin. Immunol.</source> <volume>154</volume> (<issue>1</issue>), <fpage>42</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2024.05.008</pub-id>
<pub-id pub-id-type="pmid">38761994</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujita</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kabashima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yanagi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Toyokuni</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miyaji</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease</article-title>. <source>J. Allergy Clin. Immunol.</source> <volume>156</volume>, <fpage>1769</fpage>&#x2013;<lpage>1771</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2025.09.012</pub-id>
<pub-id pub-id-type="pmid">41085498</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fyhrquist</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Karisola</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alenius</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Endotypes of atopic dermatitis</article-title>. <source>J. Allergy Clin. Immunol.</source> <volume>156</volume>, <fpage>24</fpage>&#x2013;<lpage>40.e4</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2025.02.029</pub-id>
<pub-id pub-id-type="pmid">40054744</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gangwar</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Gudjonsson</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>N. L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Mouse models of psoriasis: a comprehensive review</article-title>. <source>J. Investigative Dermatol.</source> <volume>142</volume> (<issue>3</issue>), <fpage>884</fpage>&#x2013;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2021.06.019</pub-id>
<pub-id pub-id-type="pmid">34953514</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gelfand</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Psoriasis: disease modification today, cure tomorrow</article-title>. <source>J. Investigative Dermatol.</source> <volume>144</volume> (<issue>12</issue>), <fpage>2614</fpage>&#x2013;<lpage>2615</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2024.10.004</pub-id>
<pub-id pub-id-type="pmid">39453288</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hollestein</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Asgari</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Nijsten</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis</article-title>. <source>Br. J. Dermatol.</source> <volume>190</volume> (<issue>4</issue>), <fpage>465</fpage>&#x2013;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1093/bjd/ljad371</pub-id>
<pub-id pub-id-type="pmid">37890083</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilchrest</surname>
<given-names>B. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Actinic keratoses: reconciling the biology of field cancerization with treatment paradigms</article-title>. <source>J. Investigative Dermatol.</source> <volume>141</volume> (<issue>4</issue>), <fpage>727</fpage>&#x2013;<lpage>731</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2020.09.002</pub-id>
<pub-id pub-id-type="pmid">32956650</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Glickman</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shokrian</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Large-scale blood proteomic analysis across different inflammatory skin conditions reveals extensive immune dysregulation with distinct biomarker profiles</article-title>. <source>Allergy</source>.</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gooderham</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Mrowietz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kadus</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Drda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vangerow</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Phase II randomized trial of BI 730357, an oral ROR&#x3b3;t inhibitor, for moderate-to-severe plaque psoriasis</article-title>. <source>J. Investigative Dermatol.</source> <volume>145</volume>, <fpage>1969</fpage>&#x2013;<lpage>1978.e14</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2024.12.025</pub-id>
<pub-id pub-id-type="pmid">39848568</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Falanga</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Novel stem cell therapies for applications to wound healing and tissue repair</article-title>. <source>Surg. Technol. Int.</source> <volume>29</volume>, <fpage>29</fpage>&#x2013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">27728944</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muddasani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fleischer</surname>
<given-names>Jr., A. B.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Peck</surname>
<given-names>G. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Trends in office visits for the five most common skin diseases in the United States</article-title>. <source>J. Clin. Aesthetic Dermatol.</source> <volume>15</volume> (<issue>5</issue>), <fpage>E82</fpage>&#x2013;<lpage>E86</lpage>.<pub-id pub-id-type="pmid">35642232</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guri-Lamce</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>AlRokh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maeshima</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>S. L.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Topical gene editing therapeutics using lipid nanoparticles: &#x2018;gene creams&#x2019; for genetic skin diseases?</article-title>. <source>Br. J. Dermatol.</source> <volume>190</volume> (<issue>5</issue>), <fpage>617</fpage>&#x2013;<lpage>627</lpage>. <pub-id pub-id-type="doi">10.1093/bjd/ljad528</pub-id>
<pub-id pub-id-type="pmid">38149939</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasselgren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oprea</surname>
<given-names>T. I.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Artificial intelligence for drug discovery: are we there yet?</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source> <volume>64</volume> (<issue>1</issue>), <fpage>527</fpage>&#x2013;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-040323-040828</pub-id>
<pub-id pub-id-type="pmid">37738505</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>W.-K.</given-names>
</name>
<name>
<surname>Herbig</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Newsam</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Gottwald</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>May</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Winckle</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Opportunities of topical drug products in a changing dermatological landscape</article-title>. <source>Eur. J. Pharm. Sci.</source> <volume>203</volume>, <fpage>106913</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2024.106913</pub-id>
<pub-id pub-id-type="pmid">39299467</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xfc;lp&#xfc;sch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rohayem</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reiger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Traidl-Hoffmann</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification</article-title>. <source>J. Allergy Clin. Immunol.</source> <volume>154</volume> (<issue>1</issue>), <fpage>31</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2024.04.029</pub-id>
<pub-id pub-id-type="pmid">38761999</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>J. K.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>CRISPR/Cas in dermatology: a scoping review of candidate diseases for clinical applications</article-title>. <source>JAAD Rev.</source> <volume>5</volume>, <fpage>71</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdrv.2025.05.003</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Otberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Thiede</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sterry</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Panzner</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles</article-title>. <source>J. Investigative Dermatology</source> <volume>126</volume> (<issue>8</issue>), <fpage>1728</fpage>&#x2013;<lpage>1732</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jid.5700323</pub-id>
<pub-id pub-id-type="pmid">16645589</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kottner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jacobi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hahnel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Balzer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Beeckman</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Core outcome sets in dermatology: report from the second meeting of the international cochrane skin group core outcome set initiative</article-title>. <source>Br. J. Dermatology</source> <volume>178</volume> (<issue>4</issue>), <fpage>e279</fpage>&#x2013;<lpage>e285</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.16324</pub-id>
<pub-id pub-id-type="pmid">29441525</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Advancements in skin&#x2010;mediated drug delivery: mechanisms, techniques, and applications</article-title>. <source>Adv. Healthc. Mater.</source> <volume>13</volume> (<issue>7</issue>), <fpage>2302375</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202302375</pub-id>
<pub-id pub-id-type="pmid">38009520</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Babon</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>The JAK-STAT pathway: from structural biology to cytokine engineering</article-title>. <source>Signal Transduction Targeted Therapy</source> <volume>9</volume> (<issue>1</issue>), <fpage>221</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-024-01934-w</pub-id>
<pub-id pub-id-type="pmid">39169031</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacGibeny</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Adjei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pyle</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bunick</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Ghannoum</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grada</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2024a</year>). <article-title>The human skin microbiome in health</article-title>. <source>J. Am. Acad. Dermatology</source> <volume>93</volume> (<issue>2</issue>), <fpage>329</fpage>&#x2013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2024.07.1498</pub-id>
<pub-id pub-id-type="pmid">39168311</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacGibeny</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Adjei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pyle</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bunick</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Ghannoum</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grada</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2024b</year>). <article-title>The skin microbiome in dermatologic disease</article-title>. <source>J. Am. Acad. Dermatology</source> <volume>93</volume> (<issue>2</issue>), <fpage>339</fpage>&#x2013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2024.07.1499</pub-id>
<pub-id pub-id-type="pmid">39173885</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinengo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bajpai</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Soljak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Upton</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Schmidtchen</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies</article-title>. <source>Ann. Epidemiol.</source> <volume>29</volume>, <fpage>8</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.annepidem.2018.10.005</pub-id>
<pub-id pub-id-type="pmid">30497932</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masson</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Shourick</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jendoubi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tauber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review</article-title>. <source>Am. J. Clin. Dermatology</source> <volume>23</volume> (<issue>4</issue>), <fpage>433</fpage>&#x2013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1007/s40257-022-00679-y</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neil</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Human skin explant model for the investigation of topical therapeutics</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>21192</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-78292-4</pub-id>
<pub-id pub-id-type="pmid">33273665</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niknam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akbarialiabad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Farjoud</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Kolaparambil Varghese</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Berrington de Gonz&#xe1;lez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Melin</surname>
<given-names>M. M.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Space oncology: a comprehensive scoping review</article-title>. <source>Wilderness Environ. Med.</source> <volume>36</volume> (<issue>Suppl. l</issue>), <fpage>148S</fpage>&#x2013;<lpage>171S</lpage>. <pub-id pub-id-type="doi">10.1177/10806032251349442</pub-id>
<pub-id pub-id-type="pmid">40653854</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordmann</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Anderton</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schweizer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>P. C.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Spatial proteomics identifies JAKi as treatment for a lethal skin disease</article-title>. <source>Nature</source> <volume>635</volume> (<issue>8040</issue>), <fpage>1001</fpage>&#x2013;<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-024-08061-0</pub-id>
<pub-id pub-id-type="pmid">39415009</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Trend analysis of pressure ulcers in adults 60 years and older from 1990 to 2021 using regression and Bayesian age period cohort models</article-title>. <source>Sci. Rep.</source> <volume>15</volume> (<issue>1</issue>), <fpage>25198</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-025-11027-5</pub-id>
<pub-id pub-id-type="pmid">40652100</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>C. O.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Bieber</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review</article-title>. <source>EBioMedicine</source> <fpage>103</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105121</pub-id>
<pub-id pub-id-type="pmid">38614010</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;rez-Salas</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Moreno-Jim&#xe9;nez</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Rocha-Guzm&#xe1;n</surname>
<given-names>N. E.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez-Laredo</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Medina-Torres</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gallegos-Infante</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>
<italic>In vitro</italic> and <italic>ex vivo</italic> models for screening topical anti-inflammatory drugs</article-title>. <source>Sci. Pharm.</source> <volume>91</volume> (<issue>2</issue>), <fpage>20</fpage>. <pub-id pub-id-type="doi">10.3390/scipharm91020020</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Primiero</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Janda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soyer</surname>
<given-names>H. P.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Skin 2.0: how cutaneous digital twins could reshape dermatology</article-title>. <source>J. Investigative Dermatology</source> <volume>145</volume> (<issue>1</issue>), <fpage>18</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2024.07.011</pub-id>
<pub-id pub-id-type="pmid">39230536</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prinsen</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Spuls</surname>
<given-names>P. I.</given-names>
</name>
<name>
<surname>Kottner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Apfelbacher</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chalmers</surname>
<given-names>J. R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Navigating the landscape of core outcome set development in dermatology</article-title>. <source>J. Am. Acad. Dermatology</source> <volume>81</volume> (<issue>1</issue>), <fpage>297</fpage>&#x2013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2019.03.009</pub-id>
<pub-id pub-id-type="pmid">30878565</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu&#xed;lez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bebiano</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maver</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Meesters</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Parzymies</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Targeting the complexity of <italic>in vitro</italic> skin models: a review of cutting-edge developments</article-title>. <source>J. Investigative Dermatology</source> <volume>144</volume> (<issue>12</issue>), <fpage>2650</fpage>&#x2013;<lpage>2670</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2024.04.032</pub-id>
<pub-id pub-id-type="pmid">39127929</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radstake</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Baselet</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Baatout</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Verslegers</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Spaceflight stressors and skin health</article-title>. <source>Biomedicines</source> <volume>10</volume> (<issue>2</issue>), <fpage>364</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines10020364</pub-id>
<pub-id pub-id-type="pmid">35203572</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raina</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Thakur</surname>
<given-names>V. K.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>New insights in topical drug delivery for skin disorders: from a nanotechnological perspective</article-title>. <source>ACS Omega</source> <volume>8</volume> (<issue>22</issue>), <fpage>19145</fpage>&#x2013;<lpage>19167</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.2c08016</pub-id>
<pub-id pub-id-type="pmid">37305231</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Paoli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Subbarayan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Copland</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Harwood</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A systematic review of methods used to conduct decentralised clinical trials</article-title>. <source>Br. J. Clin. Pharmacol.</source> <volume>88</volume> (<issue>6</issue>), <fpage>2843</fpage>&#x2013;<lpage>2862</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.15205</pub-id>
<pub-id pub-id-type="pmid">34961991</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shqair</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Draw</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Maya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bunick</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Akbarialiabad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schlesinger</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Advances in cell-mediated drug delivery for dermatologic diseases: mechanisms and current applications</article-title>. <source>Pharmaceutics</source> <volume>17</volume> (<issue>11</issue>), <fpage>1438</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics17111438</pub-id>
<pub-id pub-id-type="pmid">41304776</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverberg</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Guttman-Yassky</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tha&#xe7;i</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Irvine</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Stein Gold</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Blauvelt</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis</article-title>. <source>N. Engl. J. Med.</source> <volume>388</volume> (<issue>12</issue>), <fpage>1080</fpage>&#x2013;<lpage>1091</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2206714</pub-id>
<pub-id pub-id-type="pmid">36920778</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverberg</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Gooderham</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pink</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Binamer</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2024a</year>). <article-title>Combining treat&#x2010;to&#x2010;target principles and shared decision&#x2010;making: international expert consensus&#x2010;based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis</article-title>. <source>J. Eur. Acad. Dermatology Venereol.</source> <volume>38</volume> (<issue>11</issue>), <fpage>2139</fpage>&#x2013;<lpage>2148</lpage>. <pub-id pub-id-type="doi">10.1111/jdv.20229</pub-id>
<pub-id pub-id-type="pmid">38989857</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverberg</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Wollenberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tha&#xe7;i</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Legat</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>K. A.</given-names>
</name>
<etal/>
</person-group> (<year>2024b</year>). <article-title>Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials</article-title>. <source>Lancet</source> <volume>404</volume> (<issue>10451</issue>), <fpage>445</fpage>&#x2013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(24)01203-0</pub-id>
<pub-id pub-id-type="pmid">39067461</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Bieber</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guttman-Yassky</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Blauvelt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cork</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Two phase 3 trials of dupilumab <italic>versus</italic> placebo in atopic dermatitis</article-title>. <source>N. Engl. J. Med.</source> <volume>375</volume> (<issue>24</issue>), <fpage>2335</fpage>&#x2013;<lpage>2348</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1610020</pub-id>
<pub-id pub-id-type="pmid">27690741</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Society</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Key statistics for basal and squamous cell skin cancers</article-title>.</mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stonesifer</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Djavid</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Grimes</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Khaleel</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Maisel-Campbell</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Immune checkpoint inhibition in non-melanoma skin cancer: a review of current evidence</article-title>. <source>Front. Oncol.</source> <volume>11</volume>, <fpage>734354</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2021.734354</pub-id>
<pub-id pub-id-type="pmid">34988009</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swindell</surname>
<given-names>W. R.</given-names>
</name>
<name>
<surname>Michaels</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Sutter</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Diaconu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis</article-title>. <source>Genome Med.</source> <volume>9</volume> (<issue>1</issue>), <fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-017-0415-3</pub-id>
<pub-id pub-id-type="pmid">28279190</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teder-Laving</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kals</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reigo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ehin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Obj&#xe4;rtel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vaht</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Genome-wide meta-analysis identifies novel loci conferring risk of acne vulgaris</article-title>. <source>Eur. J. Hum. Genet.</source> <volume>32</volume> (<issue>9</issue>), <fpage>1136</fpage>&#x2013;<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-023-01326-8</pub-id>
<pub-id pub-id-type="pmid">36922633</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teertam</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Setaluri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ayuso</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Advances in microengineered platforms for skin research</article-title>. <source>JID Innov.</source> <volume>5</volume> (<issue>1</issue>), <fpage>100315</fpage>. <pub-id pub-id-type="doi">10.1016/j.xjidi.2024.100315</pub-id>
<pub-id pub-id-type="pmid">39525704</pub-id>
</mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The relapse of psoriasis: mechanisms and mysteries</article-title>. <source>JID Innov.</source> <volume>2</volume> (<issue>3</issue>), <fpage>100116</fpage>. <pub-id pub-id-type="doi">10.1016/j.xjidi.2022.100116</pub-id>
<pub-id pub-id-type="pmid">35601055</pub-id>
</mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsakalozou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Spires</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Polak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Mechanistic modeling of drug products applied to the skin: a workshop summary report</article-title>. <source>CPT Pharmacometrics Syst. Pharmacol.</source> <volume>12</volume> (<issue>5</issue>), <fpage>575</fpage>&#x2013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1002/psp4.12893</pub-id>
<pub-id pub-id-type="pmid">36456539</pub-id>
</mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walford</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Bautmans</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Deschamps</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>R. P.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Considerations for cell and gene therapy programs entering the clinical space</article-title>. <source>Clin. Pharmacol. Ther.</source> <volume>114</volume> (<issue>3</issue>), <fpage>569</fpage>&#x2013;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.2971</pub-id>
<pub-id pub-id-type="pmid">37309988</pub-id>
</mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>E. H. C.</given-names>
</name>
<name>
<surname>Barresi-Thornton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.-C.</given-names>
</name>
<name>
<surname>Senna</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>I. C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The development of human <italic>ex vivo</italic> models of inflammatory skin conditions</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume> (<issue>24</issue>), <fpage>17255</fpage>. <pub-id pub-id-type="doi">10.3390/ijms242417255</pub-id>
<pub-id pub-id-type="pmid">38139083</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Senescence in chronic wounds and potential targeted therapies</article-title>. <source>Burns Trauma</source> <volume>10</volume>, <fpage>tkab045</fpage>. <pub-id pub-id-type="doi">10.1093/burnst/tkab045</pub-id>
<pub-id pub-id-type="pmid">35187179</pub-id>
</mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinstock</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The struggle for primary prevention of skin cancer</article-title>. <source>Am. J. Prevent. Med.</source> <volume>34</volume> (<issue>2</issue>), <fpage>171</fpage>&#x2013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1016/j.amepre.2007.11.002</pub-id>
<pub-id pub-id-type="pmid">18201649</pub-id>
</mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinstock</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Thwin</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Marcolivio</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Means</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Leader</surname>
<given-names>N. F.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial</article-title>. <source>JAMA Dermatol.</source> <volume>154</volume> (<issue>2</issue>), <fpage>167</fpage>&#x2013;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1001/jamadermatol.2017.3631</pub-id>
<pub-id pub-id-type="pmid">29299592</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wollenberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blauvelt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Guttman&#x2010;Yassky</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Worm</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lynde</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lacour</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Tralokinumab for moderate&#x2010;to&#x2010;severe atopic dermatitis: results from two 52&#x2010;week, randomized, double&#x2010;blind, multicentre, placebo&#x2010;controlled phase III trials (ECZTRA 1 and ECZTRA 2)</article-title>. <source>Br. J. Dermatology</source> <volume>184</volume> (<issue>3</issue>), <fpage>437</fpage>&#x2013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1111/bjd.19574</pub-id>
<pub-id pub-id-type="pmid">33000465</pub-id>
</mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2024a</year>). <article-title>Microneedles as transdermal drug delivery system for enhancing skin disease treatment</article-title>. <source>Acta Pharm. Sin. B</source> <volume>14</volume> (<issue>12</issue>), <fpage>5161</fpage>&#x2013;<lpage>5180</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2024.08.013</pub-id>
<pub-id pub-id-type="pmid">39807331</pub-id>
</mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hailer</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>El Kurdi</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2024b</year>). <article-title>A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response</article-title>. <source>Sci. Immunol.</source> <volume>9</volume> (<issue>91</issue>), <fpage>eadi2848</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.adi2848</pub-id>
<pub-id pub-id-type="pmid">38277466</pub-id>
</mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liew</surname>
<given-names>P. X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2025a</year>). <article-title>Advances of bispecific antibodies using/application in dermatology: a review</article-title>. <source>Front. Allergy</source> <volume>6</volume>, <fpage>1668931</fpage>. <pub-id pub-id-type="doi">10.3389/falgy.2025.1668931</pub-id>
<pub-id pub-id-type="pmid">40909165</pub-id>
</mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2025b</year>). <article-title>Artificial intelligence in drug development</article-title>. <source>Nat. Med.</source> <volume>31</volume> (<issue>1</issue>), <fpage>45</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-024-03434-4</pub-id>
<pub-id pub-id-type="pmid">39833407</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing</article-title>. <source>Front. Pharmacol.</source> <volume>14</volume>, <fpage>1333986</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2023.1333986</pub-id>
<pub-id pub-id-type="pmid">38293666</pub-id>
</mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Targeted protein degradation: advances in drug discovery and clinical practice</article-title>. <source>Signal Transduct. Target. Ther.</source> <volume>9</volume> (<issue>1</issue>), <fpage>308</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-024-02004-x</pub-id>
<pub-id pub-id-type="pmid">39500878</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>